- LOGIN
- MemberShip
- 2025-12-18 01:17:38
- Company
- Bispecific antibodies pass reimbursement hurdle
- by Son, Hyung Min Nov 03, 2025 06:09am
- (from left) bispecific antibodies Major bispecific antibody therapies targeting hematologic cancers have successively cleared the first stage of reimbursement. With patients who have failed prior therapies desperately needing new options, attention is focused on whether these new drugs with innovative-mechanism will secure insurance reimbursement. According to industry sources on November 3, the Health Insurance Review & Assessment Service (HIRA) recently held its 8th Cancer Disease Review Committee (CDRC). At the meeting, reimbursement criteria were established for two hematologic bispecific antibodies: Janssen's 'Tecvayli (teclistamab)' and 'Pfizer's Elrexfio (elranatamab).' Multiple myeloma is a blood cancer characterized by the proliferation of abnormal plasma cells, which are created in the bone marrow, throughout the body. A relatively large number of treatments have emerged for this cancer type, with new drugs being approved for up to fifth-line treatment and beyond. Besides bispecific antibodies, various CAR-T new drugs like 'Kymriah (tisagenlecleucel)' and 'Yescarta (axicabtagene ciloleucel)' also target this disease. Due to exiting alternative like CAR-T had led to the assessment that reimbursement for bispecific antibodies would not be easy. However, limitations of CAR-T therapies include complex manufacturing processes, the time delay of over a month until administration, and the requirement for patients to maintain a certain health condition. Unlike these, bispecific antibodies are off-the-shelf anti-cancer drugs that work by simultaneously recognizing cancer cells and T-cells, activating the T-cells to indirectly eliminate the cancer cells. BCMA is a protein expressed on the surface of B cells, and CD3 is expressed on the surface of T-cells. Elrexfio and Tecvayli have a novel mechanism that induces myeloma cell death by targeting both. Elrexfio demonstrated efficacy in the MagnetisMM-3 Phase 2 study in patients who had failed three or more prior therapies. In the trial, Elrexfio showed an Objective Response Rate (ORR) of 61%, and the rate of maintained response at 15 months was confirmed to be 71%. The median Overall Survival (OS) for the Elrexfio group was 24.6 months, and the median Progression-Free Survival (PFS) was 17.2 months. Tecvayli was administered to 165 patients in the MajesTEC-1 Phase 2 study, resulting in an ORR of 63%, with a stringent Complete Response (sCR) of 32.7%, a Complete Response (CR) of 6.7%, and a Very Good Partial Response (VGPR) of 19.4%. The median time to response was 1.2 months, and the duration of response was reported to be 18.4 months. Bispecific antibodies for B-cell lymphoma also await to be reviewed bispecific antibodiesDiscussions on reimbursement for bispecific antibodies are also progressing in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL), another type of hematologic cancer. Among these, AbbVie's 'Epkinly (epcoritamab)' passed the CDRC in July, after its reimbursement criteria were established. DLBCL is the most common B-cell lymphoma, accounting for about 40% of non-Hodgkin lymphomas, and has an aggressive nature with rapid progression. The failure rate after first-line treatment reaches about 15%, and even patients who achieve CR have a relapse rate of 25% within 18 months. Although existing CAR-T therapies are reimbursed and utilized, their application to elderly patients is limited due to treatment initiation delays and neurotoxicity (ICANS). Thus, the demand for new treatments still exists. Epkinly was evaluated in the EPCORE NHL-1 Phase 1/2 study, involving 167 patients with CD20-positive relapsed or refractory DLBCL who had received two or more prior lines of therapy. The results showed an ORR of 62%, a CR of 39%, and a median Duration of Response (DOR) of 15.5 months. bispecific antibodyAttention is also focused on the re-attempt for Roche's bispecific antibody, 'Columvi (glofitamab).' Columvi was submitted to the CDRC in December last year and July this year but failed to establish reimbursement criteria. Columvi was submitted concurrently with Epkinly in December last year; however, Epkinly succeeded in passing the CDRC hurdle in June on its second attempt. Since Columvi has expanded its indication to second-line DLBCL treatment in the U.S. and Europe, Roche may be considering a simultaneous reimbursement application for both second- and third-line settings. Columvi is a treatment with a maximum duration of 12 cycles, approximately 8 months, and has a defined end of treatment. In clinical trials, Columvi showed a CR of 40%, an ORR of 52%, and a median DOR of 26.9 months for patients who achieved CR. It also recorded a 67% CR maintenance rate at 18 months.
- Company
- Olympus to redefine BPH treatment landscape with iTind
- by Hwang, byoung woo Nov 03, 2025 06:09am
- Olympus Korea is moving to reshape the urology market with its benign prostatic hyperplasia (BPH) treatment device, “iTind.” Leveraging the advantages of its non-resection, shape-memory alloy structure, the company is highlighting key features such as sexual function preservation and rapid recovery as it pushes to expand market penetration. Olympus Korea held a press conference on the 31st to outline strategies to broaden adoption at domestic clinics and improve patient accessibility following the recognition of its new health technology. (From the left) Naeun Min (UG Marketing Cell Leader), Jeongsoo Kim (SP Unit Leader), Junsoo Lee,(SP Marketing Sub-Unit Leader) Olympus Korea strengthens urology portfolio Olympus Korea already possesses a diagnostic and therapeutic portfolio for various diseases, including cancer, through medical endoscopes, laparoscopes, and surgical equipment. Its core areas are gastroenterology, respiratory, and urology, while also providing diagnostic and therapeutic solutions in otolaryngology, surgery, and other fields. In April, Olympus Korea introduced the minimally invasive BPH treatment device ‘iTind’ to the domestic market. iTind is a temporary implantable device made from Nitinol alloy. When inserted into the prostatic urethra in a folded state, it gradually unfolds at the 5 o'clock, 7 o'clock, and 12 o'clock positions in response to body temperature, gently exerting pressure on the prostatic urethra and bladder neck. This process induces localized ischemia and tissue remodeling, widening the urinary channel. The device is removed after 5–7 days via a simple procedure, leaving no foreign material behind. Junsoo Lee, SP Marketing Sub-Unit Leader at Olympus Korea, stated, “iTind is a non-incisional treatment that creates a channel without using energy, thus avoiding tissue damage. It is a minimally invasive option that preserves sexual function while offering rapid recovery.” The first domestic procedure was performed at Kangdong Sacred Heart Hospital in April. The company noted that the simple procedure enables use even at clinic-level facilities and plans gradual site expansion. Jeongsoo Kim, SP Unit Leader at Olympus Korea, added, “Unlike resection surgery, it offers differentiated value by leaving no foreign objects in the body and enabling faster recovery. It will become a new treatment strategy that reduces the burden on both patients and clinicians.” Clinical evidence-based efficacy and safety...strengths of new health technology iTind’s clinical data simultaneously demonstrated long-term efficacy and safety. In a 48-month follow-up study of 81 patients with benign prostatic hyperplasia (BPH), the International Prostate Symptom Score (IPSS) decreased by 45.3%, and maximum urinary flow rate (Qmax) increased by 114.7%. A 12-month follow-up multicenter study (120 patients) confirmed a 54.9% reduction in IPSS and a 106.6% increase in Qmax, with no reports of sexual dysfunction or ejaculation disorders. Naeun Min, UG Marketing Cell Leader at Olympus Korea, stated, “Long-term benefits have been confirmed overseas, and early domestic procedure cases show high patient satisfaction. There is no residual material in the body and no tissue deformation, reducing the burden of repeat procedures.” In this regard, Olympus disclosed on-site feedback from clinicians, noting that patients reported improved urination and a rapid return to daily life after the procedure, indicating high initial satisfaction. iTIND was officially designated as a new health technology by the Ministry of Health and Welfare in May last year and is currently used in 23 countries, including the US, Europe, and Korea. It is also listed in the American Urological Association (AUA) guidelines for benign prostatic hyperplasia (BPH), securing treatment evidence. Confidence in market expansion...“Will enhance patient accessibility to spread treatment value” According to statistics from the Health Insurance Review and Assessment Service, the number of BPH patients in Korea reached 1.61 million in 2024, a roughly 24% increase compared to five years ago (1.3 million in 2019). Pic of iTindOf these, 98% are managed with medication, driving rapid growth in demand for the minimally invasive surgical therapies (MIST) category, which bridges the gap between drugs and surgery. Currently, iTind is a non-reimbursed procedure, leading to cost variations between hospitals. This means that even with good technology, cost limitations can create access barriers. Lee noted, “Although non-reimbursed, the cost is roughly half that of existing minimally invasive procedures, improving accessibility. It’s a realistic option for patients delaying surgery or struggling with drug side effects.” In the long term, Olympus Korea is focusing on expanding adoption primarily in clinics and delivering patient-tailored treatment solutions. Lee added, “We will continue education and awareness efforts to position iTind as a low-burden treatment option. Expanding access and delivering the clinical value of iTind will be our key priorities.” Kim concluded, “Olympus Korea is expanding its medical device portfolio beyond cancer treatment to enhance patient quality of life. Beginning with iTind, we will continue delivering innovative solutions in urology and minimally invasive care.”
- Company
- Samsung Bioepis wins second trial in Eylea patent dispute
- by Kim, Jin-Gu Nov 03, 2025 06:08am
- Samsung Bioepis has overturned a prior loss and secured victory in the second-instance trial on invalidating the formulation patent for Eylea (aflibercept). The ruling strengthens expectations that commercial sales of its Eylea biosimilar ‘Afilivu’ may resume. According to industry sources on the 31st, the Patent Court on Oct. 30 ruled in favor of Samsung Bioepis in its lawsuit seeking invalidation of Regeneron’s registered patent. This patent pertains to the composition of Aflibercept. It centers on formulation technology to ensure stable preparation of aflibercept, the main component of Eylea, at high concentrations (40-50mg/mL) as a ‘VEGF antagonist formulation suitable for intravitreal administration’. Samsung Bioepis filed a patent invalidation trial in December 2022. In October last year, the Intellectual Property Trial and Appeal Board (IPTAB) partially dismissed and partially rejected the petition, siding with Regeneron. Following the IPTAB ruling, domestic sales of Samsung Bioepis’ biosimilar Afilivu were suspended in Korea. Based on that decision, Regeneron had filed both a main patent-infringement lawsuit and a preliminary injunction request for sale suspension, and the court granted the injunction in May this year. Samsung Bioepis contested this, filing a lawsuit with the Patent Court to overturn the IPTAB ruling. One year later, the Patent Court reversed the earlier decision and ruled in favor of Samsung Bioepis. As a result, prospects are rising that Afilivu sales may resume. Because the preliminary injunction relied on the IPTAB decision, observers expect the injunction may now be lifted following the Patent Court ruling. The company is also seen gaining a strategic advantage in its broader legal battle with Regeneron. In addition to this invalidation lawsuit, Samsung Bioepis has appealed an earlier loss in the injunction case. The main patent infringement lawsuit is ongoing at the first-instance level.
- Company
- "Kisqali's adjuvant therapy, results from the NATALEE study"
- by Hwang, byoung woo Nov 03, 2025 06:07am
- The 5-year follow-up results of the NATALEE study, unveiled at the European Society for Medical Oncology (ESMO Congress 2025), are drawing significant attention. The data suggest the potential for further widening of the long-term survival curves across a broad patient population, including lower-risk groups such as node-negative patients. This evidence is evaluated as expanding the potential for 'complete remission access' in early breast cancer treatment. Im Seock-Ah of Seoul National University Hospital's Division of Hematology-Medical Oncology assessed that "Patients who are node-negative (N0) or have 1-3 positive nodes often relapse at 5th-7th year," and said, "The preventive effect in this late-relapse patient group will further widen the long-term survival gap." "3-year dosing design, clear evidence for inhibiting early recurrence" Im Seock-Ah of Seoul National University HospitalHormone Receptor-positive (HR+) / HER2-negative (HER2-) breast cancer is known to account for approximately 70% of all breast cancers. Furthermore, it is reported that one-third of stage 2 patients and over half of stage 3 patients experience recurrence even after the standard Endocrine Therapy (ET). The NATALEE study is a Phase 3 clinical trial evaluating the long-term recurrence prevention effect of Kisqali (ribociclib, 400mg, 3 weeks on/1 week off) combination therapy compared to non-steroidal aromatase inhibitor (NSAI) monotherapy in 5,101 patients with high-risk stage 2-3 HR+/HER2- early breast cancer. Regarding Kisqali's adjuvant therapy design, Professor Im explained, "The peak of recurrence is most pronounced between 2 and 3 years post-surgery. Continuing treatment for three years to cover this period has clear clinical evidence." She stated, "We have pharmacodynamic data showing that target inhibition is possible even at the 400mg dose, and the suppression of early recurrence is the key factor that widens the gap between the future iDFS and OS curves." The current Hazard Ratio (HR) in the NATALEE study is around 0.8, already indicating a positive outcome. Professor Im assessed that the study is following the same trend as the monarchE study of Verzenio (abemaciclib), which demonstrated improvement in Overall Survival (OS) in its 7-year follow-up analysis. Professor Im emphasized, "As the follow-up of the NATALEE study continues, OS improvement will clearly become visible within 3-4 years." She stressed, "Even an absolute benefit of 2-3% in adjuvant therapy is clinically significant, and the large-scale design of breast cancer studies is intended to secure this statistical power." "Reducing non-reimbursement burden... high economic acceptance" Professor Im also mentioned that patient access to Kisqali in clinical practice is relatively high, although it is currently non-reimbursed. She said, "Novartis is trying to improve price accessibility, and some patients can receive assistance from private insurance," and added, "The perception of it being a 'high-cost new drug' has decreased since it has been used for over seven years in metastatic breast cancer." Professor Im believes that patients view the cost not as spending millions of KRW to live a few more months with metastatic cancer, but as investing a significantly smaller amount to 'live a healthy life forever.' This perspective results in a relatively high rate of patients choosing the drug in clinical practice. However, the patient burden due to the non-reimbursed status still exists. Professor Im also shared her view that simply differentiating between overlapping patient populations when future reimbursement is applied would not be desirable. She emphasized, "Since there are patients who need to switch to Kisqali due to side effects from abemaciclib, or vice versa, the system should allow for flexible patient choice based on individual circumstances." She stressed, "Restrictions like 'you can't use this because an alternative drug exists' ultimately limit patient freedom. The system should be more open based on scientific evidence." Finally, Professor Im concluded by stressing the importance of 'precision medicine' as the future direction for breast cancer treatment, alongside discussions on treatment access. She stated, "Although breast cancer treatment is nearing a cure, there is a need to precisely differentiate the biological differences between the patient group that rapidly progresses early on and the long-term survival group." Professor Im also pointed out, "Genomic testing and biomarker analysis are the answers, but since they are not covered by insurance, the patient burden reaches 80%." He added, "Genuine long-term survival is only possible when medical professionals' scientific judgment is trusted and the system adopts a more flexible approach."
- Company
- JW Pharm's in-licensed drug ' Tavalisse' can be prescribed
- by Eo, Yun-Ho Oct 31, 2025 06:12am
- JW Pharmaceutical's new drug under contract, 'Tavalisse,' is now available for prescription at general hospitals. According to industry sources, immune thrombocytopenic purpura (ITP) treatment Tavalisse (fostamatinib) has passed the drug committees (DC) of 'Big 5' tertiary general hospitals, including Samsung Medical Center, Sinchon Severance Hospital, and medical institutes, including Incheon St. Mary's Hospital, Jeonbuk National University Hospital, and Chungbuk University Hospital. After receiving insurance reimbursement approval in July, this drug is quickly expanding its prescription areas. Tavalisse is the first Spleen Tyrosine Kinase (SYK) inhibitor approved in Korea. It has a mechanism inhibiting platelet destruction. It works by blocking the activation of Fc gamma (γ) receptors, which regulate the immune response, thereby suppressing excessive immune reactions and preventing thrombocytopenia. This drug was developed by the U.S. pharmaceutical company Rigel Pharmaceuticals and obtained U.S. FDA approval in 2018. Tavalisse was designated as an orphan drug in the United States (2015), Japan (2020), and Korea (2021). In 2018, Japan's Kissei Pharmaceutical secured the development and commercialization rights for Japan, China, Korea, and Taiwan from Rigel Pharmaceuticals. Consequently, JW Pharmaceutical signed a license-in agreement with Kissei Pharmaceutical in 2021 for domestic development and sales rights. According to the Korean Society of Hematology's ITP Clinical Practice Guidelines, corticosteroids and immunoglobulins are recommended as first-line treatments. If ITP persists long-term, splenectomy or thrombopoietin receptor agonists (TPO-RAs) are used as second-line treatments. However, some patients do not achieve sufficient efficacy with existing treatments, necessitating the development of a new treatment option. Tavalisse can serve as an alternative for these patients. Meanwhile, Tavalisse is reimbursable for adult patients with chronic immune thrombocytopenia who are refractory to corticosteroids and immunoglobulins. The reimbursement criteria apply to patients with a platelet count leq 20,000/㎕ or with a platelet count of 20,000 to 30,000/㎕ who also have clinically significant bleeding (such as central nervous system disease, gastrointestinal bleeding, or ocular bleeding).
- Company
- Lotte Biologics·SK Pharmteco jointly target global ADC mkt
- by Cha, Jihyun Oct 31, 2025 06:12am
- Letter of Intent signing ceremony between Lotte Biologics and SK Pharmteco (Source: Lotte Biologics) Lotte Biologics (CEO James Park) and SK Pharmteco (CEO Joerg Ahlgrimm) announced on the 30th that they have signed a Letter of Intent (LOI) for strategic business collaboration to strengthen their competitiveness in the global Antibody-Drug Conjugate (ADC) market. The signing ceremony took place at the Lotte Biologics booth at ‘CPHI Worldwide 2025’, the world's largest pharmaceutical and biotech industry held in Frankfurt, Germany. Executives from both companies, including James Park, CEO of Lotte Biologics; Yoo-Yeol Shin, Head of Global Strategy; Joerg Ahlgrimm, CEO of SK Pharmteco; and Andrew Penny, CCO. Through the collaboration, the two companies plan to jointly provide an integrated, one-stop CDMO service based on various ADC-specialized solutions to potential customers in the global market. Lotte Biologics will leverage its cGMP manufacturing capabilities and global quality competitiveness at the Syracuse Bio Campus in the U.S. to provide ADC-specific CDMO services from API manufacturing to conjugation. SK Pharmteco will be responsible for the chemical synthesis processes, including linkers and payloads. By optimizing and combining each company’s respective expertise, the companies aim to establish a full-cycle CDMO system, deliver customized integrated services, expand order intake through joint marketing, and secure global clients through joint marketing. Furthermore, they aim to address the clients’ overall chemical, manufacturing, and control (CMC) requirements and present an integrated technology and operational platform that minimizes gaps between development and manufacturing. Lotte Biologics expects to provide differentiated value to customers based on its credibility and quality competitiveness as a global bio CDMO. This is underpinned by its antibody conjugation production infrastructure at its Syracuse, USA facility, global client service experience, and track record of flawless FDA inspections. Lotte Biologics further explained that this agreement, leveraging the synergies of the production infrastructures in the U.S. and Europe, will also enable a strategic response to the ongoing US-driven supply chain restructuring and rising bio-reshoring demands. James Park, CEO of Lotte Biologics, said, “This collaboration represents a significant achievement as the pharmaceutical-biotech affiliates of Korea's leading companies join forces on the global stage for the first time. We will strive to secure a competitive advantage in next-generation modalities such as ADCs and demonstrate the potential of K-Bio on the global stage.” Joerg Ahlgrimm, CEO of SK Pharmteco, said, “This strategic partnership will accelerate the development of next-generation therapy, enabling both companies to deliver greater value and bring innovative new drugs to patients around the world faster.”
- Company
- "Severe COVID-19 cases continue to rise...infection control"
- by Son, Hyung Min Oct 30, 2025 06:11am
- Joon Young Song, Professor of Infectious Diseases at Korea University Guro HospitalMore than two years after the COVID-19 pandemic transitioned to an endemic phase, the number of severe cases, particularly among high-risk groups, continues to occur steadily. 'The shadow of infection' remains in clinical practice. While the number of confirmed cases is not surging as before, hospitalizations and severe cases are persisting, especially among vulnerable populations. Joon Young Song, Professor of the Department of Infectious Diseases at Korea University Guro Hospital, said, "Many high-risk patients hospitalized with severe symptoms like pneumonia are confirmed with COVID-19." He added, "These patients face risks of prolonged hospitalization, deterioration of physical function, and death from severe infection." Professor Song also said, "Most patients hospitalized for pneumonia are elderly or immunocompromised, both high-risk groups. Since recovery is slow and the possibility of complications is high, prevention through vaccination is essential." According to Professor Song, age is the most significant risk factor for COVID-19, with the risk of progression to a severe case increasing significantly with age in those 65 and older. Immunocompromised individuals are at a very high risk of severe infection. An analysis of vaccine efficacy and disease burden, conducted in the 'Host-based Influenza Morbidity & Mortality Study' involving eight medical institutions, including Korea University Guro Hospital, showed a high risk of COVID-19 infection and severe disease among immunocompromised patients, such as cancer patients and chronic kidney disease patients. Dialysis patients are also classified as high-risk. Since hospital dialysis rooms are confined spaces where multiple patients receive treatment, an infection can rapidly spread into an outbreak, with most cases carrying a high risk of progression to severe infection. Experts are increasingly viewing COVID-19 as a seasonal respiratory illness, actively recommending vaccination and raising awareness of the disease. Professor Song said, "In recent years, COVID-19 has shown a pattern of recurrent outbreaks twice a year, during summer and winter," and stressed, "The severe risk must be lowered through regular vaccination, just like with the flu." However, public awareness of the importance of vaccination has decreased as the endemic transition progresses. According to Professor Song, even patients who absolutely need the vaccine, such as cancer patients, often hesitate due to concerns like 'Will I get a fever?' or 'Will it interfere with my anti-cancer treatment?' if their physician does not absolutely recommend it. Professor Song emphasized that if a cancer patient contracts COVID-19 without being vaccinated, there is a high probability that their anti-cancer treatment must be suspended or that the infection will progress to a severe illness, such as pneumonia. Professor Song assessed, "The preventive effect against severe infection remains over 70% and is maintained for about 10 months after vaccination. For high-risk groups, such as the older adults aged 65 and over or those with underlying conditions like heart failure or lung disease, the priority is reducing hospitalization and death resulting from severe infection, pneumonia, acute respiratory illness, and the worsening of underlying diseases, rather than just preventing the infection itself." He also emphasized, "It is crucial for medical professionals to fully explain the necessity and safety of vaccination to patients and actively recommend it." "Safety of vaccination against COVID-19·flu at the same time, and the need to boost coverage" The government began the National Immunization Program (NIP) for both flu and COVID-19 vaccines on October 15. Simultaneous vaccination of the two is possible. This year's vaccine strain is LP.8.1 strain, a variant that began circulating last year. Recently, sub-variants that have evolved from LP.8.1 strain, such as NB.1.8.1 strain and XFG strain, have been increasing. Experts assess that, since these variants are sublineages of the Omicron lineage, the LP.8.1 variant vaccine provides sufficient protection. Immunogenicity evaluation has confirmed a high level of cross-immunity against these sub-variants with the LP.8.1 vaccine. Professor Song said, "As COVID-19 repeats its annual outbreaks, it is significant that the government has officially decided to support vaccination for the age groups and patient populations who absolutely require it." Pfizer received approval for its 'Comirnaty LP.8.1' vaccine targeting the LP.8.1 variant in August. Notably, Pfizervaccine comes in a pre-filled syringe (PFS) formulation. While multi-dose vials may have slight dosage errors, PFS offers the advantage of administering the correct, predetermined dose in a single-use syringe. PFS is also considered safer in terms of infection control. Professor Song commented, "The latest COVID-19 vaccines have confirmed sufficient preventive efficacy. The currently circulating variant viruses do not have large mutational differences, so the vaccines introduced domestically can be expected to provide sufficient protection against the latest variants." He added, "Like the flu vaccine, the COVID-19 vaccine requires regular administration. It is difficult to say which of the two diseases is more severe definitively, but both COVID-19 and influenza pose a high disease burden for those aged 65 and older." However, the COVID-19 vaccine initially had a lower vaccination rate than the flu vaccine, due to a perception that it was difficult to tolerate and caused many side effects. While the influenza vaccination rate for those aged 65 and older currently reaches about 85%, the COVID-19 vaccination rate was 45% at the end of last year and 47.9% as of April this year. Therefore, recommending concurrent vaccination of both is necessary to boost COVID-19 vaccination rates. Professor Song explained, "The events after COVID-19 vaccine administration are a condition resulting from immune boosting. However, from the third dose onward, the frequency and intensity of general adverse events, such as fever and fatigue, have decreased. The incidence of myocarditis, which was a concern among young people, has also decreased significantly. We believe that these concerns will gradually improve as COVID-19 vaccines are administered repeatedly." He also expressed that the safety of concurrent vaccination is not an issue. He said, "Concurrent vaccination has not increased the frequency of adverse events, and no severe cases have been reported. Various studies have all confirmed that simultaneous vaccination with the COVID-19 vaccine and the influenza vaccine is safe." Professor Song added, "Simultaneous vaccination plays an important role in increasing vaccination rates. Administering both vaccines during a single visit prevents patients from missing their vaccination window. In fact, a significant number of patients who received the COVID-19 vaccine did so simultaneously with the influenza vaccine." Finally, Professor Song said, "Academic societies are cooperating with the KDCA to continue communicating the necessity of the COVID-19 vaccine through various media and are continuing activities like campaigns." He stressed, "Misinformation or distorted reports related to vaccines, once spread, are often perceived as facts by the public and are difficult to correct. Therefore, actively sharing accurate information and continuously educating and promoting the safety and necessity of vaccines is important."
- Company
- 'Januvia generics hit 23% market share in 2 years'
- by Kim, Jin-Gu Oct 30, 2025 06:11am
- Generic versions of the DPP-4 inhibitor class diabetes treatment ‘Januvia (sitagliptin)’ series expanded their market share to 23% just two years after launch. However, analysis indicates their market penetration pace is slower than that of previous cases such as Tenelia (teneligliptin) and Galvus (vildagliptin). Performance among generic manufacturers varied significantly. While most generics recorded quarterly prescription sales below KRW 100 million, Kyongbo Pharmaceutical and Hanmi Pharmaceutical achieved results exceeding KRW 1 billion, strengthening their presence. Januvia generics hit 23% share in 2 years — market penetration slower According to the pharmaceutical market research institution UBIST on the 29th, total outpatient prescriptions for sitagliptin monotherapy and sitagliptin/metformin combinations in Q3 this year reached KRW 28.3 billion, down 6% from KRW 30.2 billion in the same quarter last year. While the sales of original products declined, generics grew. Sales of the original Januvia, Janumet, and Janumet XR fell 14%, from KRW 25.1 billion in Q3 2023 to KRW 21.7 billion this year. Specifically, Januvia dropped from KRW 5.8 billion to KRW 4.5 billion, and sales of Janumet/Janumet XR combined declined from KRW 19.3 billion to KRW 17.2 billion. Since the launch of the generics, the originals have seen a steady downward trend. Just before patent expiry in Q2 2023, total prescriptions for the Januvia series stood at KRW 37.5 billion, but after generics entered in Q4 2023, the figure fell to KRW 26.6 billion, then dropped further 18% by Q3 this year. Meanwhile, generic products saw their combined prescription sales increase by 30% over the past year, rising from KRW 5.1 billion to KRW 6.6 billion. Sales of Januvia generics increased from KRW 1.6 billion to KRW 1.9 billion, while Janumet and Janumet XR generics rose from KRW 3.5 billion to KRW 4.7 billion. Januvia generics were released in September 2023. Following the patent expiration of the long-standing market leader of the KRW 600 billion annual DPP-4 inhibitor market, many generic companies rushed to join in the competition. A total of 89 companies received approval for generics, and 60 of these companies launched products. The overall market share of generics expanded from 17% to 23% within a year. However, the pace of the market penetration is somewhat slower compared to other DPP-4 inhibitor generics like Tenelia and Galvus. Galvus and Galvusmet generics recorded a 42% market share in their first year. In its second year, it further expanded its share to 47%, reaching a level similar to the original. Tenelia and Tenelia M generics surpassed the original with a 54% market share in their first year. This rose to 58% in their second year. Sales of Hanmi·Kyongbo soar... Most other companies record quarterly prescription sales under KRW 300 million Generic companies showed polarized results. Only two companies recorded quarterly prescription sales exceeding KRW 1 billion, while most others fell short of even KRW 100 million. Kyongbo Pharmaceutical reported KRW 1.1 billion in Q3 sales for its combination generics Janustinmet and Janustin XR, nearly doubling from KRW 600 million in the same quarter last year. Cumulative prescriptions for the two products have reached KRW 4.9 billion. Hanmi Pharmaceutical’s Sita and Sitamet XR posted KRW 1 billion, up 25% year-over-year, bringing cumulative prescriptions to KRW 5.8 billion since launch. In contrast, most generics are underperforming. Of the 60 companies that launched products, 41 (68%) posted quarterly sales below KRW 100 million, and 15 companies (25%) recorded less than KRW 300 million. The average Q3 prescription per company stood at approximately KRW 110 million. The reason Januvia generics are struggling to expand their influence is that the DPP-4 inhibitor class diabetes treatment market is already saturated. In this space, Januvia competes with original products such as Zemiglo (gemigliptin), Trajenta (linagliptin), Tenelia (teneligliptin), Suganon (evogliptin), Galvus (vildagliptin), Onglyza (saxagliptin), Nesina (alogliptin), and Guardlet (alogliptin/metformin). Among these, Galvus, Tenelia, and Trajenta have already faced generic competition upon their patent expiry. Furthermore, the DPP-4 inhibitor market has seen a decline in overall prescription volume since the emergence of SGLT-2 inhibitor class diabetes treatments like Forxiga and Jardiance. In this environment, the flood of Januvia and Janumet generics has led to fierce competition and lower-than-expected sales performance.
- Company
- Wegovy prescribed to adolescents for obesity
- by Son, Hyung Min Oct 30, 2025 06:09am
- Novo Nordisk held an event on the 28th at the Courtyard by Marriott Seoul Namdaemun for its obesity treatment drug Wegovy, which has settled as a leading therapy for adult obesity, has expanded its reach into adolescent obesity. Following approvals in the US and Europe, Novo Nordisk’s Wegovy can now be prescribed to patients aged 12 and older in Korea. With this, calls from the medical community on earlier intervention for obesity are gaining traction. Experts describe this approval as “not merely an expansion of indication, but an institutional turning point recognizing adolescent obesity as a chronic disease.” Adolexcent obesity moves out of the treatment blind spot Novo Nordisk held a press conference on the 28th to mark the expanded adolescent indication for its obesity treatment Wegovy (semaglutide 2.4mg), sharing key clinical results and future treatment strategies. Wegovy is a once-weekly GLP-1 (glucagon-like peptide-1) receptor agonist approved last year in Korea for treating adult obesity. With the new indication, it can now be used for adolescent patients aged 12 and above in Korea, emerging as a new treatment option for obesity during the growth years. According to Novo Nordisk, semaglutide 2.4mg is structurally similar to human GLP-1. It regulates overall metabolism not only through weight loss but also by improving blood glucose and lipid levels. Ju Ok Lim, Head of Medical Affairs at Novo Nordisk, said, “Semaglutide 2.4mg demonstrated consistent weight loss effects and safety not only in adults but also in adolescents. The indication expansion will serve as an opportunity to address the treatment gap for adolescent obesity.” Until now, obesity treatments available for children and adolescents aged 12 and older in Korea have been extremely limited. Representative options include the fat absorption inhibitor ‘orlistat’ and the once-daily GLP-1 class injectable ‘Saxenda (liraglutide)’. Latest adult-targeted medications like ‘Qsymia (phentermine/topiramate)’ and ‘Mounjaro (tirzepatide)’ are not yet approved for adolescent use. The approval of Wegovy expands access to weekly therapy-based treatment approaches. Julie Broe Honore, Head of clinical development, medical and regulatory affairs at Novo Nordisk, said, “Adolescent obesity is no longer an individual problem but a public health issue. This expansion of Wegovy's indication marks the first step toward preventing adult metabolic diseases through early intervention.” STEP TEENS study…16% weight reduction & improved cardiovascular risk factors This expansion of Wegovy's indication is based on results from the Phase III STEP TEENS clinical trial conducted in adolescents. The study involved 201 adolescents aged 12-18 who were obese or overweight and had weight-related conditions, conducted over 68 weeks. The average age was 15.4 years, 62% were female, and the racial distribution was 79% White, 8% Black, and 2% Asian. Clinical results showed the Wegovy group achieved an average BMI (Body Mass Index) reduction of 16.1%, demonstrating a significant difference compared to the placebo group, which increased by 0.6%. Approximately 72.5% of patients achieved at least a 5% weight loss, nearly four times higher than the placebo group (17.7%), with an average weight loss of 15.3 kg. Notably, 37.4% of patients achieved a weight loss of 20% or more, demonstrating efficacy in adolescents comparable to that seen in adults. Improvements were observed not only in cardiovascular risk factors like waist circumference, blood pressure, and lipid levels, but also in quality of life (QoL) indicators. Eun-gu Kang, Professor of Pediatrics at Korea University Ansan HospitalThe main adverse reactions reported were gastrointestinal symptoms such as nausea, vomiting, and diarrhea, but most were mild and did not affect growth or pubertal development. Eun-gu Kang, Professor of Pediatrics at Korea University Ansan Hospital, commented, “Beyond weight reduction, the study confirmed metabolic benefits such as LDL cholesterol reduction and improvements in blood pressure and waist circumference, suggesting positive cardiovascular implications.” He further noted, “However, as adolescents are still in the process of growth, long-term follow-up and accumulation of safety data are necessary.” Adolescent obesity rate increases 1.7 times over 10 years Experts unanimously agreed that this approval holds significance in terms of ‘securing treatment accessibility’. According to the ‘2024 Adolescent Health Behavior Survey’ conducted by the Korea Disease Control and Prevention Agency and the Ministry of Education, the obesity rate among middle and high school students rose from 7.5% in 2015 to 12.5% last year, a 1.7-fold increase over 10 years. The overweight/obesity rate for male students is 43.0%, and for female students, 24.6%, the highest among the four East Asian countries, including China, Japan, and Taiwan. The main concern is comorbidities. Around 80% of obese adolescents remain obese into adulthood and often develop one or more metabolic disorders, such as hypertension, diabetes, or dyslipidemia. Yong-hee Hong, Professor of Pediatrics at Soonchunhyang University Bucheon HospitalThis is why experts point out that adolescent obesity should be viewed not as a mere ‘cosmetic issue’ but as a disease requiring early intervention. Yong-hee Hong, Professor of Pediatrics at Soonchunhyang University Bucheon Hospital, emphasized “Obesity is clearly a disease requiring treatment, yet it is often still perceived as a cosmetic issue. This perception must change so that patients who actually need medication can be brought into the healthcare system.” Young-sung Suh, Professor of Family Medicine at Keimyung University Dongsan Hospital and President of the Korean Society for the Study of Obesity, stated, “Obesity is not a matter of willpower but a complex metabolic disorder. At the society level, we will focus on enhancing treatment accessibility while ensuring safe medication use and preventing misuse.” While some raise concerns about muscle loss with GLP-1 agonists, experts see significant clinical benefits due to their fat-focused weight reduction. Lim said, “Some muscle loss may occur with weight reduction, but overall, the health benefits from fat loss are far greater. We will strengthen education and management to enable healthy weight loss alongside the metabolic improvement.” Kang added, “While muscle loss in patients during growth periods requires caution, GLP-1 drugs often yield positive outcomes in body composition changes. Controlling fat mass and maintaining nutritional balance are more important than just body weight numbers.”
- Company
- Reimb for Perjeta as adjuvant therapy under CDDC review
- by Eo, Yun-Ho Oct 29, 2025 06:12am
- The expansion of reimbursement coverage for Perjeta’s use as adjuvant therapy in breast cancer is drawing attention. According to industry sources, Roche Korea’s HER2-positive breast cancer treatment Perjeta (pertuzumab) has been submitted for review by the Health Insurance Review and Assessment Service (HIRA) Cancer Disease Deliberation Committee. Currently, Perjeta is reimbursed for treating HER2-positive metastatic or unresectable locally recurrent breast cancer. In early breast cancer, it is granted selective reimbursement as a neoadjuvant therapy (before surgery), with patients bearing 30% of the cost. However, in the postoperative adjuvant therapy stage—a key treatment step to prevent recurrence—has remained non-reimbursed (100% patient coinsurance) since its indication was added in Korea in 2018, limiting patient access. The recent submission to the National Health Insurance Service's Drug Disease Deliberation Committee is believed to have been significantly influenced by the 10-year long-term follow-up data from the Phase III APHINITY clinical trial, presented at the European Society for Medical Oncology Breast Cancer Conference (ESMO Breast Cancer 2025) last May. This study newly confirmed statistically significant final overall survival (OS) data for the combination of Perjeta and Herceptin (trastuzumab). When Perjeta was administered in combination with Herceptin and chemotherapy, the risk of death in patients with HER2-positive early breast cancer was reduced by 17% compared to the existing Herceptin-chemotherapy combination therapy. Furthermore, the 10-year survival rate in the Perjeta-Herceptin treatment arm was 91.6%, showing an improvement compared to the 89.8% in the control arm. The Perjeta-Herceptin treatment arm also demonstrated greater clinical benefit in patients at high risk of recurrence. Specifically, in a subgroup analysis of patients with lymph node–positive disease, who are at high risk of recurrence, the combination showed a 21% reduction in the risk of death. Furthermore, the benefit in invasive disease-free survival (iDFS) was also maintained, reaffirming the earlier findings of the APHINITY study. It remains to be seen whether Perjeta's adjuvant therapy indication can pass CDDC review and ultimately be granted reimbursement coverage. Meanwhile, the Perjeta and Herceptin combination is currently recommended as Category 1 adjuvant therapy in the U.S. NCCN Guidelines for patients with HER2-positive early breast cancer and lymph node metastasis. It is also recommended as Category 1 adjuvant therapy for high-risk, lymph node–positive patients who achieved pathological complete response (pCR) after neoadjuvant chemotherapy.
